ORMP oramed.com: Price-to-Projected Revenue Ratio
Oramed Pharmaceuticals is implementing innovative capsules for injection-free insulin administration, ensuring sustainable demand. Its Israeli origin and humanitarian status minimize geopolitical threats. The forward P/S trend visualizes market expectations, where the current parameter equals 84.30. Moving away from needles in favor of oral forms radically reduces medical waste, supporting ESG principles.
ORMP (oramed.com): analytical breakdowns and indicator data
- market price and analyst price targets:
- company stock capitalization data:
- book value of equity indicators:
- debt and solvency information:
Total Debt to Capital Oramed Pharmaceuticals|ORMP - Long-Term Liabilities to Capital|Short-Term Debt to Capital Oramed Pharmaceuticals Inc.|ORMP - Company Aggregate Debt|Debt to Book Value ORMP|ORMP - Company Long-Term Loans and Borrowings|Company Short-Term Debt Oramed Pharmaceuticals|Quick Ratio oramed.com
- financial results and valuation multiples details:
ORMP - Final Profit|Projected Future Earnings Oramed Pharmaceuticals|ORMP - P/E Multiple|Future Price to Earnings Oramed Pharmaceuticals Inc.|ORMP - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ORMP|ORMP - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Oramed Pharmaceuticals|ORMP - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth oramed.com|ORMP - Net earnings per share growth this year|Earnings growth forecast for next year Oramed Pharmaceuticals
- total revenue and sales volume data:
Fundamental company valuation:Oramed Pharma (ORMP)
Reliable distribution and strict supply chain control of oral insulin at Oramed Pharmaceuticals (ORMP) create the foundation for projected sales growth. Reflecting the ratio of market capitalization to expected revenue for the coming year, the forward price-to-sales valuation trend allows investors to assess the premium for future business expansion rates and identify risks of multiple compression in a timely manner.
Key competitors
Price-to-Projected Revenue Ratio Haleon HLN|Kenvue Inc (KVUE) - Market Cap to Future Revenue Ratio|VRNA - Price-to-Projected Revenue Ratio|Forward Price to Sales MENS (Jyong Bio)|LGND: Forward P/S Multiple|amneal.com (AMRX) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Perrigo|Forward Price-to-Revenue Multiple Alvotech S.A. (ALVO)|Forward P/S Multiple LQDA|GLPG - Market Cap to Future Revenue Ratio|Forward P/S Multiple ANIP (ANI Pharmaceuticals)|MNKD: Market Cap to Projected Revenue|AMPH: Forward Price-to-Revenue Multiple|Forward Price to Sales PCRX (Pacira Pharmaceuticals)|ARS Pharma (SPRY) - Price-to-Projected Revenue Ratio|Future Price to Revenue TBPH (Theravance Corp)|AQST (Aquestive Therapeutics) - Forward P/S Multiple|SCPH: Forward Price to Sales|Forward P/S Multiple TECX|Forward P/S Multiple Tonix Pharma (TNXP)|Price-to-Projected Revenue Ratio China SXT Pharmaceuticals, Inc. SXTC|Forward Price to Sales EPRX|BHST - Price-to-Projected Revenue Ratio|invizyne.com (EXOZ) - Forward Price-to-Revenue Multiple|ENTX: Forward P/S Multiple|MindWalk Holdings, Inc. (HYFT) - Forward P/S Multiple|ABVC (ABVC BioPharma Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Cumberland Corp (CPIX)|Forward P/S Multiple QNTM|FGEN - Market Cap to Future Revenue Ratio|Telomir Pharmaceuticals, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple Rani Therapeutics Holdings RANI|SNYR: Forward Price-to-Revenue Multiple|Rallybio Corporation - Price to Expected Revenue Ratio|LEXX: Forward P/S Multiple|PULM - Market Cap to Expected Sales Ratio|PTHL (Pheton Holdings Limited) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Aptorum (APM)|Forward P/S Multiple LYRA|Forward P/S Multiple Impact BioMedical, Inc. (IBO)|Price-to-Projected Revenue Ratio TNF Pharmaceuticals, Inc. TNFA|cbdMD Inc. - Price-to-Projected Revenue Ratio|PRFX - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Altamira Therapeutics CYTO|Lipella (LIPO) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio OptiNose Corp (OPTN)|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals|PROC: Forward Price to Sales|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|Forward Price-to-Revenue Multiple Qilian International Holding Group QLI|Price-to-Projected Revenue Ratio ACELYRIN, Inc. SLRN|TFFP (TFF Pharmaceuticals, Inc) - Future Price to Revenue
